Souvien Therapeutics, Ltd.

Souvien Therapeutics, Ltd. is a biotechnology company focused on developing novel therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.

Souvien is founded on the pioneering research of Dr. Li-Huei Tsai, PhD, the Director of The Picower Institute for Learning and Memory at MIT, and Associate Professor Dr. Stephen Haggarty, PhD, the director of the Chemical Neurobiology Laboratory at Harvard Medical School/Massachusetts General Hospital.

The development plan is based on a substantial body of data implicating a critical epigenetic regulator of cellular aging in neurodegeneration. The goal is to use that knowledge, and the greatly evolving understanding of aging, to bring new drugs into human trials.